Trajan Group Holdings Ltd · ASX:TRJ
Trajan — FY2021 Earnings Presentation
19 slides from Trajan's earnings presentation, Aug 25, 2021
Slide 1: FY21 Full Year Results Update
FY21 Full Year Results Update Stephen Tomisich, CEO and Managing Director, August 2021
Slide 2: About Trajan
About Trajan Science that benefits people Global developer and manufacturer of analytical and life sciences products and devices. Founded to have a positive impact on human wellbeing through scientific measurement. • Products and solutions used in the analysis of biological, food and environmental s
Slide 3: We Delivered Impact
We Delivered Impact Science that benefits people In the fields of proteomics and genomics our precision tubing is designed to underpin reliability and confidence in analytical results. In FY21 we saw that translate to accelerated adoption. *PEEKSil® and MS Emitter Tip revenues grew by more than 30%
Slide 4: We Delivered Impact
We Delivered Impact Science that benefits people Through partnering with best practice manufacturers in anatomical pathology we aim to optimize tissue presentation for diagnosis. In FY21 we estimate more than 500,000 patients benefitted from slide and blade technologies commercialized by Trajan. Tra
Slide 5: We Delivered Impact
We Delivered Impact Science that benefits people Our Automation and Dispensing Syringe product lines helped drive progress in pharmaceutical drug discovery and development, both vital areas of human health science Trajan’s Automation business grew by more than 30% in FY21. (On a constant currency ba
Slide 6: We Delivered Impact
We Delivered Impact Science that benefits people Trajan’s microfluidics platform “Silflow®” is enabling new GC system designs intended to improve chemical separations in environmental analysis Revenue from “Silflow®” grew by 26% in FY21. (On a constant currency basis)
Slide 7: Strong Progress in New Technologies
Strong Progress in New Technologies Science that benefits people hemaPEN® • Example of Trajan’s new and disruptive technology suite approaching commercialization. • Synexa reported the capability to monitor human immune system response to COVID-19 vaccines without the patient requiring a venous bloo
Slide 8: Strong Progress in New Technologies
Strong Progress in New Technologies Science that benefits people Hummingbird • Modular miniaturized HPLC instrument system in development. • Pharmaceutical industry continued its evaluation of early prototypes providing positive feedback. • Holds potential to bring measurement capability directly to
Slide 9: FY21 Performance Highlights
FY21 Performance Highlights Science that benefits people 16%* 89.0% $76.6M Organic $9.95M Total Proforma EBITDA Revenue Revenue EBITDA Growth Growth * Constant currency basis • Revenue, margins and profitability in line with prospectus forecast. • Results achieved despite forex headwind. • Growth ac
Slide 10: Delivered on Prospectus Forecast
Delivered on Prospectus Forecast Science that benefits people FY21 Proforma Results Forecast Actual Variation % Variation ($1,000) ($1.000) ($1,000) Revenue $74,648 $76,566 + $1,918 + 2.6% $GP $29,983 $30,787 + $804 + 2.7% %GP 40.2% 40.2% OPEX $20,526 $20,834 + $308 + 1.5% OPEX % 27.5% 27.2% EBITDA
Slide 11: Growth Continues
Growth Continues Science that benefits people Trajan Revenue, $M %GP $76.6 40.2% $67.8 $71.8 39.8% 37.0% FY19 FY20 FY21 FY19 FY20 FY21 Proforma EBITDA %EBITDA 13.0% $9.95 8.0% 7.3% $5.45 $5.27 FY19 FY20 FY21 FY19 FY20 FY21 Note: All R&D expensed.
Slide 12: Growth Across Broad Customer Set
Growth Across Broad Customer Set Science that benefits people FY21 growth of top 20 customers (on constant currency basis) 75% 34% 33% 34% 20% 19% 21% 22% 17% 17% 15% 14% 12% 11% 4% 1% 1% 6% A B C D E F G H I J -2% K L M N O P Q R S T -9%
Slide 13: FY22 Acceleration As a Public Company
FY22 Acceleration As a Public Company Science that benefits people • Activity underway to leverage IPO funds: • Progressing acquisition targets. • Delivering margin gains through operational infrastructure and improvements. • Accelerating commercialization of new technologies.
Slide 14: FY22 M&A
FY22 M&A Science that benefits people • Actively working on several potential acquisitions. • Scale of targets range from revenues of <$1M pa to circa $25M pa. • Generally, targets operate in the fields of precision liquid handling, data analytics, automation, chromatography consumables and consumer
Slide 15: FY22 Acceleration of Margin Expansion
FY22 Acceleration of Margin Expansion Science that benefits people • “Project Neptune” a management proposal to drive operational gains through automation, scrap reduction and acceleration of further utilisation to Trajan’s Penang and US facilities has commenced. • Additional investment through FY22
Slide 16: FY22 New Technology Commercialization
FY22 New Technology Commercialization Science that benefits people • Three primary targets for investment based on their demonstrated utility to date: • hemaPEN®: “Healthy heart” related biomarker monitoring, COVID-19 Antibody response and Therapeutic Drug Monitoring. • Hummingbird: Decentralized me
Slide 17: FY22 Acceleration as a Public Company
FY22 Acceleration as a Public Company Science that benefits people • In summary in FY22 we expect: • Underlying performance to continue to align with the IPO prospectus forecasts. The IPO forecast did not contemplate the deployment of the IPO funds. • With IPO funds we expect to: • Complete one or m
Slide 18: Disclaimer
Disclaimer Science that benefits people The material in this presentation is general background information about Trajan Group Holdings Limited (Trajan) and is current at the date of the presentation, [25 August 2021]. The information in the presentation is provided for information purposes only, is
Slide 19: Q&A
Q&A Science that benefits people